AB-PA01
AXP000223.1 · Phage therapy
- Platform
- phage cocktail (fixed composition)
- Originator
- AmpliPhi Biosciences
- Sponsor
- Armata Pharmaceuticals
Names
| Name | Type | Source |
|---|---|---|
| AB-PA01 | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Pseudomonas aeruginosa bacteriophage (cocktail)
- Replication
- replicating
- Route
- intravenous, inhaled
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03395743 | Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic | No longer available |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38347019 | Lytic activity of phages against bacterial pathogens infecting diabetic foot ulcers. | Scientific reports | 2024 | name in abstract: AB-PA01 |
| PMID 32443619 | Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms. | Viruses | 2020 | name in abstract: AB-PA01 |
Notes
Anti-Pseudomonas aeruginosa phage product used under emergency/compassionate access, including three lung transplant recipients (Aslam 2019, Am J Transplant 19:2631-2639) and a ventilator-associated pneumonia case given it intravenously and by inhalation; US expanded-access record NCT03395743. Distinct from the later AP-PA02.
How to cite
AB-PA01 (AXP000223.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000223.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.